|This Slide: #14 of 100|
Slide #14. Concordia Healthcare Corp. — Donnatal
Concordia Healthcare Corp. (CXR.CA)
Concordia Healthcare Corp. (Concordia or the Company) (TSX: CXR) (OTCQX: CHEHF), announced today that it has entered into a definitive agreement to acquire Donnatal, an adjunctive therapy in the treatment of irritable bowel syndrome ("IBS") and acute enterocolitis, from a privately held specialty pharmaceutical company carrying on business as Revive Pharmaceuticals ("Revive Pharmaceuticals").
Concordia International is an integrated, specialty healthcare company focused on the acquisition of legacy pharmaceutical products, the acquisition and development of orphan drugs, and distribution of medical devices servicing the diabetic population.
Open the CXR.CA Page at The Online Investor »